The Indonesia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US $6.6 Mn in 2022, and is predicted to grow at (CAGR) of 5.8% from 2023 to 2030, to US $10.4 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, healthcare infrastructure, economic growth, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, Regulus, among others
The Indonesia Autosomal Dominant Polycystic Kidney Disease Therapeutics Market is at around US $6.6 Mn in 2022 and is projected to reach US $10.4 Mn in 2030, exhibiting a CAGR of 5.8% during the forecast period.
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition affecting multiple systems caused by mutations in the genes PKD1 and PKD2. This often progresses to kidney failure (ESKD) in majority of patients. Common symptoms encompass pain, recurring infections, and fatigue. Although incurable, managing ADPKD aims at averting complications and addressing symptoms. Tolvaptan (Jinarc) by Otsuka Pharmaceuticals, an approved medication for ADPKD, functions as a vasopressin blocker, reducing cyst development in a subset of patients. Pain management, lifestyle adjustments, and various medications targeting associated issues like hypertension constitute additional treatment options.
The prevalence of ADPKD is around 1 in every 1,000 individuals in Indonesia. Approximately 1,00,000–5,00,000 people in Indonesia are currently expected to be living with ADPKD. The market is therefore driven by major factors like increased prevalence of cases, government initiatives, and increased awareness in the population, allowing heightened diagnosis. However, conditions such as high costs of advanced treatment, limited scope of research and development, and others hinder the growth and potential of the market.
Market Growth Drivers
Surge in the prevalence of ADPKD: The prevalence of ADPKD is 1 in every 1,000 individuals in Indonesia. It is estimated that there are around 1,00,000–5,00,000 Indonesian people surviving with this condition. These numbers are anticipated to result in patients requiring advanced treatments, resulting in the growth of the market.
Government initiatives: Government efforts and private funding are enhancing access to medical facilities and diagnostic resources, which could result in improved identification and care for individuals with ADPKD. Indonesia's National Health Insurance (JKN) scheme offers fundamental healthcare coverage for the majority of the population, potentially widening access to crucial ADPKD treatments and care methods.
Increased awareness: Increased awareness of ADPKD within the professional community and among the general population, supported by advocacy groups, prompts earlier diagnosis and a surge in demand for treatment choices. Groups such as the Indonesian Society of Nephrology work towards improving patient access and care, influencing evidence-based policy decisions that propel the therapeutics market.
Market Restraints
High costs of treatment: Tolvaptan, the prevailing primary medication for ADPKD, alongside potential upcoming therapies, may still pose financial challenges for patients despite JKN coverage. This could burden patients financially, potentially limiting treatment accessibility and leading to non-adherence or delays, affecting the market's outreach.
Dependence on Imported Medicines: Indonesia heavily depends on imported medications for ADPKD, leaving the market vulnerable to currency fluctuations and potential disruptions in the supply chain. This situation can affect patient access and treatment consistency, introducing instability that could hinder market growth.
Limited research and development: In contrast to other significant markets, Indonesia’s involvement in ADPKD research might be relatively limited, which could slow down the development and accessibility of new treatment options for patients. This situation restricts market diversity and the potential for innovation.
Indonesia's healthcare landscape is governed by a complex web of authorities, with the Ministry of Health (MOH) as the central hub. This ministry shapes national health policies, drives medical reforms, and oversees healthcare services nationwide.
To navigate this landscape, therapeutic companies must comply with regulations set by various agencies, including the National Agency for Food and Drug Control (BPOM). Obtaining licenses for healthcare products, such as pharmaceuticals and medical devices, requires both MOH and BPOM approval. This involves rigorous scrutiny of technical and scientific data to ensure product safety, quality, and effectiveness.
Despite the complexities, Indonesia's dynamic healthcare system presents diverse opportunities for companies. Both the public and private sectors offer opportunities for businesses involved in the healthcare industry
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Treatment
By Route of Administration
By End User
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.